Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 9Phase NA 5Phase 4 4Phase 2/3 2Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Vomiting 2Weight Loss 1Nausea 1Melanoma 1Anorexia 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Palonosetron × Clear all
NCT01046240 2015-01-27

Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy

Clinica Universidad de Navarra, Universidad de Navarra

Phase 1/2 Completed
29 enrolled

Vomiting

NCT00412425 2012-05-04

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

M.D. Anderson Cancer Center

Phase 1/2 Completed
30 enrolled 4 charts
Dermatologic

Anorexia, Melanoma, Nausea, Vomiting, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡